SAM #HHS-OMAS-2026-10

FedRAMP Moderate Authorization Services for Revvity Signals ELN

HHS awarded Revvity Signals Software, Inc. a sole-source contract to complete FedRAMP Moderate authorization for the NIH-selected Revvity Signals ELN platform. - Government buyer: Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS); the award notice also identifies the OMAS Strategic Buying Center – Information Technology. - OEM and vendor: Revvity Signals Software, Inc., developer and proprietary owner of Revvity Signals ELN. - Services requested: Complete FedRAMP Moderate authorization for the existing ELN platform, including project management, security control remediation, interoperability configuration and validation, technical documentation, and preparation and submission of the authorization package. - The platform supports chemistry-focused laboratory research and electronic research data management. The work requires direct access to Revvity proprietary source code, system architecture, and development environment. - The award is fixed-price and sole-source, valued at $2,007,319.81. The notice states that market research found no other capable provider and that an earlier effort left remediation, interoperability validation, and final package submission unfinished.

Description

Based on the market research conducted, the Government proceeded with a fixed-price, sole-source acquisition with Revvity Signals Software, Inc. (Revvity) for the services necessary to obtain FedRAMP Moderate authorization for the Revvity Signals Electronic Lab Notebook (ELN), supporting compliance with NARA/OMB requirements for the transition of Federal records to electronic formats. The contractor is responsible for providing the services necessary to obtain FedRAMP Moderate authorization for the Revvity Signals ELN, including project management, gap remediation, interoperability assurance, and preparation and submission of the FedRAMP authorization package. Revvity is the developer and sole proprietary owner of the Revvity Signals ELN platform used by the National Institutes of Health (NIH). As the software owner, Revvity has exclusive access to the platform’s source code, system architecture, and internal development environment. Such access is necessary to perform the security control remediation, interoperability configuration, and technical documentation required to achieve FedRAMP Moderate authorization. No other company, including resellers, integrators, or third-party consultants, has the technical access or authority necessary to modify the Revvity platform to satisfy these requirements. On August 7, 2026, the Government posted a Notice of Intent and invited capability statements from vendors that believed they were capable of performing the work specified in the notice. Responses were due by 9:00 a.m. on August 14, 2026. Four vendors submitted timely responses; however, none demonstrated the technical capability necessary to perform the required services. Specifically, the respondents lacked the proprietary access and requisite authority to perform the necessary FedRAMP remediation activities on the Revvity platform, and none provided a viable approach for obtaining or otherwise addressing the required access and authority. Accordingly, the market research did not identify an alternative source capable of meeting the Government’s requirements, and the acquisition proceeded on a sole-source basis with Revvity.

View original listing